Scheme showing the signaling elements and frequent deregulations in the Hh signaling network and potential cross-talk with the EGFR signaling pathway involved in the malignant behavior of cancer cells
Scheme showing the signaling elements and frequent deregulations in the Hh signaling network and potential cross-talk with the EGFR signaling pathway involved in the malignant behavior of cancer cells. The molecular events associated with the cellular processing of the SHH precursor into a biologically active form via autocatalytic cleavage and lipid modifications are illustrated. Autocrine and paracrine stimulation of the cancer cells by the monomeric and multimeric SHH molecules is also illustrated. The repressive effect of SUFU on the GLI activity is shown. Moreover, the frequent deregulations, including overexpression of the SHH ligand; inactivating mutations in HHIP, PTCH, or SUFU; or activating mutations in SMO coreceptor, which may contribute to cancer development, are also indicated. The potential stimulatory effect induced by the activation of EGFR pathway and oncogenic mutations in K-RASmut and B-RAFmut on the GLI transcriptional activity is indicated. The target gene products induced through the activation of Hh and EGFR signaling pathways are also described. Moreover, the stimulatory effect induced through the activation of TGF-β/TGF-βR/Smad3-Smad4 and Wnt/β-catenin on the GLI2 expression is illustrated. In addition, the potential inhibitory effect induced by diverse pharmacological agents, such as a mAb directed against SHH ligand, EGF, EGFR, and Wnt, selective inhibitors of SMO (cyclopamine, KAAD-cyclopamine, IPI-269609, or GDC-0449), EGFR tyrosine kinase activity (gefitinib and erlotinib), TGF-β type I activin receptor-like kinase, and ALK5 (SB431542) are also indicated. COX2, cyclooxygenase 2; CXCR4, CXC chemokine receptor 4; FOXM1, forkhead box M1 transcription factor; MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor.
Frequent Deregulations in the Hedgehog Signaling Network and Cross-Talks with the Epidermal Growth Factor Receptor Pathway Involved in Cancer Progression and Targeted Therapies. (2010)
Murielle Mimeault, et al. Pharmacol Rev. 2010 Sep;62(3):497-524. Figure: F6.